

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/535,000
Applicants : Masakazu HATANO et al.
Filed : May 16, 2005
For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
 β -BLOCKER
Art Unit : 1617
Examiner : Gigi Georgiana HUANG
Docket No. : 05318/HG
Confirm No. : 1033
Customer No.: 01933

**INFORMATION DISCLOSURE STATEMENT
FILED CONCOMITANTLY WITH RCE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP RCE

S I R :


Submitted herewith are the following:

A. Copies of the following documents relating to a demand for a Trial for Invalidation in the corresponding Japanese Patent 4314433 (Japanese Patent Application No. 2000-564663):

Document (1) : Demand for Trial and a partial English-language translation thereof (including a DECLARATION of accuracy of translation of Gihei Nakamura dated November 22, 2010);

Express Mail Mailing Label
No.: EM 501 329 131 US
Date of Deposit: January 14, 2011

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 with sufficient postage on the date indicated above and is addressed to:
MAIL STOP RCE
Commissioner for Patents,
P.O. Box 1450
Alexandria, VA 22313-1450


Dorothy DeFrancesco

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by payment herewith, authorization is hereby given to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.

- Document (2) : Exhibit No. 1 in said Trial for Invalidation, namely, Japanese National Patent Publication No. 7-508030 and the corresponding published International Application, namely WO 93/23082;
- Document (3) : Exhibit No. 3 in said Trial for Invalidation, namely Japanese national Patent Publication No. 2001-509780 (the corresponding published International Application, namely WO 97/23222 is of record in the above-identified application);
- Document (4) : Exhibit No. 5 in said Trial for Invalidation, namely "Gekkan Ganka Shinryo Practice (Practical Ophthalmology)," 42. Tenganyaku no Tsukaikata (How to Use Eye Drops), 1999, pp. 52-53 and a partial English-language translation thereof (including a DECLARATION of accuracy of translation of Gihei Nakamura dated October 28, 2010);
- Document (5) : Exhibit No. 6 in said Trial for Invalidation, namely "Gekkan Yakuji (The Pharmaceuticals Monthly)," 1996, Vol. 38, No. 9, pp. 2311-2331 and a partial English-language translation thereof (including a

DECLARATION of accuracy of translation of
Gihei Nakamura) dated October 28, 2010;

Document (6) : Exhibit No. 12 in said Trial for
Invalidation, namely Am. J. Physiol. Cell
Physiol., 278, C57-C65, (2000);

Document (7) : Exhibit No. 16 in said Trial for
Invalidation, namely the Notice of Grounds
of Rejection drafted on August 27, 2007 in
connection with Japanese Patent Application
No. 2000-564663 and a partial English-
language translation thereof (including a
DECLARATION of accuracy of translation of
Gihei Nakamura dated October 28, 2010); and

Document (8) : Board Decision for said Trial for
Invalidation and a partial English-language
translation thereof (including a DECLARATION
of accuracy of translation of Gihei Nakamura
dated November 22, 2010).

B. An IDS form identifying the aforesaid documents.

The applicants have informed the undersigned that although
there was a demand for a Trial for Invalidation regarding the


corresponding Japanese patent, the patent was judged to be valid at the conclusion of the proceedings.

As shown hereinbelow, the following Exhibits listed in the enclosed BOARD DECISION are identified in the following INFORMATION DISCLOSURE STATEMENTS (IDS) which are of record in the above-identified application:

<u>Exhibit No.</u>	<u>Document</u>	<u>Date of IDS</u>
2	WO 00/09162	June 27, 2005
4	<u>Nature</u> , (1997), Vol. 389, pp. 990-994	June 27, 2005
6	<u>Expert Opinion of Emerging Drugs</u> , (2002), Vol. 7, No. 1, pp. 141-163	August 16, 2007
7	<u>Drugs</u> , (2000), Vol. 59, No. 3, pp. 411- 434	June 27, 2005
9	<u>Invest. Ophthalmol. Vis. Sci.</u> , (2001), Vol. 42, No. 1, pp. 137-144	June 27, 2005
10	<u>Invest. Ophthalmol. Vis. Sci.</u> , (2001), Vol. 42, No. 5, pp. 1029- 1037	June 27, 2005

It is respectfully requested that an initialed copy of the enclosed IDS Form be returned to indicate that all the documents listed therein have been considered and made of record.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

HOLTZ, HOLTZ, GOODMAN & CHICK PC
220 FIFTH AVENUE, 16th FLOOR
NEW YORK, NEW YORK 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: RBARTH@HHPATENT.COM
RSB/ddf